经动脉化疗栓塞术及钇-90治疗肝癌和其他病变。

Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.

作者信息

Minocha Jeet, Salem Riad, Lewandowski Robert J

机构信息

Division of Interventional Radiology, Department of Radiology, University of Illinois Hospital & Health Sciences System, 1740 West Taylor Street (MC 931), Chicago, IL 60612, USA.

Section of Interventional Radiology, Department of Radiology, Robert H. Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, 676 North Saint Clair Street, Suite 800, Chicago, IL 60611, USA.

出版信息

Clin Liver Dis. 2014 Nov;18(4):877-90. doi: 10.1016/j.cld.2014.07.007. Epub 2014 Aug 22.

DOI:10.1016/j.cld.2014.07.007

PMID:25438288

Abstract

Transarterial chemoembolization (TACE) is the recommended treatment of intermediate stage hepatocellular carcinoma (HCC). Radioembolization with yttrium 90 has overcome the shortcomings of external beam radiation in the treatment of liver cancer. TACE and radioembolization have led to encouraging response, survival, and quality of life outcomes, with reduced toxicity profiles. This result has led to the use of these therapies in patients with hepatic metastases, most commonly from colorectal cancer. This article reviews the current state of the practice of TACE and radioembolization and presents recent scientific data that support their role in the treatment of HCC and hepatic metastatic disease.

摘要

经动脉化疗栓塞术（TACE）是中期肝细胞癌（HCC）的推荐治疗方法。钇90放射性栓塞术克服了外照射治疗肝癌的缺点。TACE和放射性栓塞术已取得了令人鼓舞的反应、生存率和生活质量结果，且毒性特征有所降低。这一结果促使这些疗法被用于肝转移患者，最常见的是结直肠癌肝转移患者。本文综述了TACE和放射性栓塞术的当前应用现状，并介绍了支持它们在HCC和肝转移疾病治疗中作用的最新科学数据。